CAS 1809885-32-2

EC5026

CAS: 1809885-32-2

EC5026 (BPN-19186) has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.

Fórmula: C₁₈H₂₃F₄N₃O₃

Pureza: 96.6% - 99.81%

Cor e Forma: Solid

Peso molecular: 405.39

Ref: TM-T11147

(S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea

CAS: 1809885-32-2

Fórmula: C₁₈H₂₃F₄N₃O₃

Pureza: 95%

Cor e Forma: Solid

Peso molecular: 405.3871

Ref: IN-DA01KASI

EC5026

CAS: 1809885-32-2

EC5026

Pureza: ≥95%

Peso molecular: 405.39g/mol

Ref: 54-BUP16218

(S)-1-(3-Fluoro-4-(Trifluoromethoxy)Phenyl)-3-(1-(2-Methylbutanoyl)Piperidin-4-Yl)Urea

CAS: 1809885-32-2

(S)-1-(3-Fluoro-4-(Trifluoromethoxy)Phenyl)-3-(1-(2-Methylbutanoyl)Piperidin-4-Yl)Urea

Pureza: 98%

Peso molecular: 405.39g/mol

Ref: 54-PC108496

(S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea

CAS: 1809885-32-2

Fórmula: C₁₈H₂₃F₄N₃O₃

Pureza: 98%

Peso molecular: 405.394

Ref: 10-F547156

EC5026

CAS: 1809885-32-2

EC5026 is a drug that has been shown to have anti-inflammatory properties. It was found to suppress the production of pro-inflammatory cytokines such as IL-6 and TNF-α in wild-type mice in an oral dosage form. EC5026 also inhibits the production of inflammatory mediators such as prostaglandin E2, leukotriene B4, and epoxyeicosatrienoic acids. The drug has been shown to inhibit the expression of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). Inhibition of these enzymes leads to increased activation of cannabinoid receptors, which are involved in pain regulation.
EC5026 is not addictive and does not cause any changes in blood pressure or heart rate when administered orally at doses that have been shown to be effective for treatment of chronic inflammation.

Fórmula: C₁₈H₂₃F₄N₃O₃

Pureza: Min. 95%

Peso molecular: 405.4 g/mol

Ref: 3D-JXC88532